| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-090 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 第四届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海皓元医药股份有限公司（以下简称"公司"）于 2025 年 7 月 18 日在 上海市浦东新区张衡路 1999 弄 3 号楼公司会议室以现场结合通讯方式召开了第 四届董事会第九次会议。本次会议的通知于 2025 年 7 月 15 日以专人送达及电 子邮件方式发出。本次会议由公司董事长郑保富先生召集和主持，会议应出席 董事 7 名，实际出席董事 7 名。本次会议的召集和召开符合《中华人民共和国 公司法》（以下简称"《公司法》"）和《上海皓元医药股份有限公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 具体内容详见公司于同日在上海证券交易所网站（www ...

1、公司符合《管理办法》《2023 年限制性股票激励计划（草案）》（以 下简称"《激励计划（草案）》"）等法律法规、规范性文件规定的实施股权 激励计划的情形，公司具备实施股权激励计划的主体资格。符合《2023 年限制 性股票激励计划实施考核管理办法》规定的第二个解除限售期解除限售条件的 要求，未发生《激励计划（草案）》中规定的不得解除限售的情形。 2、本次可解除限售的 6 名激励对象符合《公司法》《证券法》等法律、法 规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市 规则》等法律、法规和规范性文件规定的激励对象条件，符合本次激励计划规 定的激励对象范围，其作为本激励计划激励对象的主体资格合法、有效，激励 对象获授的第一类限制性股票的解除限售条件已经成就。 综上，董事会薪酬与考核委员会认为：公司具备实施股权激励计划的主体 资格，未发生不得解除限售的情形，本次可解除限售的 6 名激励对象解除限售 资格合法有效，本次激励计划第二个解除限售期解除限售条件已经成就，将于 2025 年 7 月 24 日届满。本次可解除限售的第一类限制性股票数量为 119,000 股， 占本核查意见出具日前一日公司总股 ...

上海皓元医药股份有限公司 董事会薪酬与考核委员会关于 2023 年限制性股票激励计划 第二类限制性股票第二个归属期 归属名单的核查意见 2025 年 7 月 18 日 上海皓元医药股份有限公司（以下简称"公司"）董事会薪酬与考核委员会 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板 上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范 性文件和《上海皓元医药股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，对公司 2023 年限制性股票激励计划（以下简称"本次激励计划"） 第二类限制性股票第二个归属期归属名单进行审核，发表核查意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文 件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件，符合本次激励计划规定的激励对象范围， 其作为公司本次激励计划激励对象的主体资格合法、有效。本次激励计划 ...

Group 1 - The core theme of the event is "Capital Assists New, Industry Revitalizes," focusing on how capital support enables the sustainable growth of innovative enterprises in the science and technology sector [2] - The event features discussions with leaders from Borui Pharmaceutical and Haoyuan Pharmaceutical, highlighting their experiences in leveraging capital for innovation and industry empowerment [2] - The Shanghai Stock Exchange and Yicai Media are collaborating to launch the "Value and Investment" column, aiming to enhance communication between listed companies, research institutions, and investment organizations [1][2] Group 2 - The second episode of the program coincides with the sixth anniversary of the Sci-Tech Innovation Board, which is expected to facilitate the development of high-quality technology enterprises through new policies and supportive systems [1] - The event will be available for viewing on Yicai's official website and app on July 18, 2025, at 15:00 [3]

Group 1 - The pharmaceutical sector is showing strong performance, particularly in innovative drugs, generic drugs, and animal vaccines, driven by the recent policy changes from the National Healthcare Security Administration [1] - The 11th batch of drug procurement initiated by the National Healthcare Security Administration excludes innovative drugs from the procurement scope, which is expected to protect the profit margins of innovative drug companies [1] - The CXO and research service sectors have seen significant gains, with companies like WuXi AppTec and Boteng Co. reporting substantial Q2 performance increases, indicating a positive trend in the sector [1] Group 2 - The innovative drug sector is identified as the most clearly defined and growth-oriented sub-industry within the pharmaceutical sector, with a recommendation to actively embrace and allocate resources to this area [2] - The rapid growth of License Out transactions is providing substantial cash flow for innovative drug companies, supporting their core pipelines in overseas markets [2] - There is an expectation for continued domestic market share growth for Chinese innovative drugs due to policy support and improved product capabilities, despite foreign companies holding a significant portion of the market [2]

Group 1 - The company issued 8,223,500 convertible bonds with a total value of 82,235,000 RMB, each with a face value of 100 RMB, and a maturity of 6 years [1][2] - The controlling shareholder, Shanghai Anxu Information Technology Co., Ltd., acquired 2,653,870 bonds, representing 32.27% of the total issuance [2] - From July 8 to July 14, 2025, the controlling shareholder reduced its holdings by 925,460 bonds, bringing the total holdings down to 1,728,410 bonds, which is 21.02% of the total issuance [2]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-089 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 公司控股股东上海安戌信息科技有限公司（以下简称"安戌信息"）配售 "皓元转债"2,653,870 张，约占可转债发行总量的 32.27%。 二、可转债持有变动情况 关于控股股东可转债持有比例变动达到 10%的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债配售情况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 ...

Core Viewpoint - The Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the biopharmaceutical sector [1][3]. Market Performance - As of July 11, 2025, the Biopharmaceutical Index rose by 1.23%, with notable gains from stocks such as Yifang Biotech (+10.31%), Shouyao Holdings (+8.34%), and Te Bao Biotech (+7.18%) [1]. - The Jiashi Science and Technology Medicine ETF (588700) also increased by 1.14%, marking its third consecutive rise [1]. Liquidity and Trading Volume - The Jiashi Science and Technology Medicine ETF recorded a turnover rate of 9.54% and a trading volume of 21.11 million yuan [3]. - Over the past month, the ETF has maintained an average daily trading volume of 33.32 million yuan, ranking first among comparable funds [3]. Fund Growth and Performance - In the last two weeks, the Jiashi Science and Technology Medicine ETF's scale increased by 17.56 million yuan, leading among comparable funds [3]. - The ETF's net value has risen by 37.70% over the past year, with a maximum single-month return of 23.29% since its inception [3]. Top Holdings - As of June 30, 2025, the top ten weighted stocks in the Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare, BeiGene, and Huatai Medical [3][5]. Policy Support and Market Outlook - Recent policy documents have been released to support the high-quality development of innovative drugs, highlighting government backing for the sector [6]. - The number of innovative drugs in development in China has reached over 4,000, representing approximately 30% of the global total [5][6].

Core Viewpoint - The announcement details the listing and circulation of restricted shares related to the acquisition of assets by Shanghai Haoyuan Pharmaceutical Co., Ltd, with a total of 4,493,210 shares set to be listed on July 16, 2025 [1][9]. Summary by Sections Listing of Restricted Shares - The company will list 4,493,210 restricted shares, which were issued to specific investors for asset acquisition and fundraising [1][2]. - The shares were registered on December 22, 2022, following approval from the China Securities Regulatory Commission [2]. Changes in Share Capital - Following the issuance of shares, the total share capital of the company increased from 104,078,810 shares to 106,982,272 shares [2]. - The company’s total share capital further increased to 150,217,339 shares after a capital increase of 0.40 shares per existing share was approved [3]. Performance Compensation - The shareholders involved in the asset acquisition, including WANG YUAN and others, are required to fulfill performance compensation obligations due to unmet performance commitments by the acquired company [6][8]. - A total of 47,725 shares were repurchased and canceled as part of the performance compensation process, reducing the total share capital to 211,561,848 shares [7]. Compliance and Verification - The independent financial advisor confirmed that the shareholders have adhered to their commitments regarding the lock-up period and performance compensation [8][9]. - The listing of the restricted shares complies with relevant regulations and the company’s disclosure is deemed accurate and complete [9]. Details of the Restricted Shares - The total number of restricted shares being listed represents 2.12% of the company's total share capital as of July 7, 2025 [10].

民生证券股份有限公司 关于上海皓元医药股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联交易之 部分限售股上市流通的核查意见 民生证券股份有限公司（以下简称"民生证券"、"独立财务顾问"）作为上 海皓元医药股份有限公司（以下简称"皓元医药"、"公司"、"上市公司"）本次 发行股份及支付现金购买资产并募集配套资金暨关联交易的独立财务顾问，根据 《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办法》 《上市公司证券发行注册管理办法》《上海证券交易所科创板股票上市规则》等 有关法律法规和规范性文件的要求，对皓元医药发行股份及支付现金购买资产并 募集配套资金暨关联交易之部分限售股上市流通事项进行了核查，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 11 月 25 日出具的《关于同意上海 皓元医药股份有限公司向 WANG YUAN（王元）等发行股份购买资产并募集配 套资金注册的批复》（证监许可[2022]3042 号），皓元医药获准向 WANG YUAN （王元）、上海源盟企业管理咨询合伙企业（有限合伙）（以下简称"上海源盟"）、 宁波九胜创新医药 ...